Aragen Cell Line Development And Process Development Solutions For Biologics CHO CLD Platforms

CHO CLD platforms

• CHO DG44, CHO GS, CHOZN, SP 2/0
• Our in-house developed CHO DG44 platform can deliver titer >4g/L in 5 months CHO GS: Up to 6g/L- Royalty Free, milestone payment free, difficult-to-express proteins, NBEs, and Animal Health
• Over 100 CLD programs Pre-IND/GMP
• Over 14 in Clinical development and 3+ commercial production

Key Attributes

• RapTr2022 with HIGH TITER and REDUCED TIMELINE
• Royalty-free CHO DG44 best suited for Biosimilar development
• Royalty free, accelerated timeline for DG44 and CHO GS (18 weeks from transfection to RCB)
• Transfection to single cell clone evaluation in 18 weeks with Aragen’s optimized process
• Our CLD platform uses a chemically defined serum free medium and proof of clonality to support IND filing
• Strong Analytical capabilities – Early engagement to establish quality and select right clones to advance

Aragen’s Process Development Services

Aragen offers coefficient upstream and downstream process development

• We use nonproprietary commercially available media and feed for screening studies this allows transfer to any CDMO
• Media and feed screening in Shake Flasks
• Process parameter screening and optimization in AMBR250
• Process consistency and scalability happens in 1L, 5L & 10L Bioreactor

Downstream Process Development

Key Attributes

• Ambr250 platform for Upstream Process development- Synergies to reduce time to IND
• Fully automated AMBR250 24 units, integrated to NOVA Flex-2 & Vi-Cell
• Multifactorial DOE to screen process parameters like- pH, DO, Temp, agitation etc
• Process parameter Optimization and identifying best operative parameters
• History of generating Biosimilar cell line- now in market